Vitamins and mineralsOmega-3 and cod liver oil — do they really protect the heart and brain?
- Henryk Różański — witasteryna F, czyli witamina F
- Paul Clayton — Dieta a nasze przeznaczenie
- Paul Clayton — Twoje oszukane serce
- Andrzej Frydrychowski — Czy tłuszcze są nam niezbędne?
- The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. · Adv Nutr 2025
- BMI Affects the Relationship between Long Chain N-3 Polyunsaturated Fatty Acid Intake and Stroke Risk: a Meta-Analysis. · Sci Rep 2015
- The Role of Omega-3 Polyunsaturated Fatty Acids in Heart Failure: A Meta-Analysis of Randomised Controlled Trials. · Nutrients 2016
- Fish and human health: an umbrella review of observational studies. · Int J Food Sci Nutr 2022
- Orthomolecular Medicine News Service — Omega 3 Fatty Acids and Cardiovascular Disease
Henryk Różański links omega-3 to heart benefits, while Paul Clayton says commercial fish oil does not protect.
- Paul Clayton points to protection from eating oily fish and a lower cardiovascular risk with a higher omega-3 index.
- Paul Clayton cautions that commercial fish oils have no documented benefits of this kind, and their oxidation may promote atrial fibrillation.
- On the brain, Andrzej Frydrychowski says fats are very important, but does not state directly that omega-3 or cod liver oil protects it.
What the authors write
Omega-3 fatty acids counter atherosclerosis and reduce the risk of heart attack and embolism.
Eating oily fish has been linked to protection from heart disease and stroke, but such protection has not been attributed to lean fish or commercial fish oil.
A higher omega-3 index has been linked to a lower risk of cardiovascular disease and a longer life.
Paul Clayton considers that commercial and pharmaceutical fish oils do not provide the documented benefits attributed to oily fish or omega-3 combined with polyphenols.
Paul Clayton suspects that oxidation of omega-3 fatty acids after consumption may increase the formation of products that promote atrial fibrillation.
Omega-3 fatty acids have anti-inflammatory effects.
Andrzej Frydrychowski stresses that the quality of fat matters for the brain, but does not identify omega-3 or cod liver oil as a way to protect the brain.
Research from PubMed · Europe PMC
We selected 4 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 406.
A meta-analysis found that high doses of omega-3 taken for at least a year improved ejection fraction and exercise capacity in people with heart failure.
Aim of the study: Heart failure is a progressive condition associated with a high mortality rate. Despite advancements in treatment, many patients continue to experience less-than-ideal outcomes.
Results: No significant differences were found in dropout rates or all-cause mortality between the n-3 PUFAs and control groups. Long-term, high-dose n-3 PUFA supplementation, particularly with a predominance of docosahexaenoic acid or eicosapentaenoic acid, enhances cardiac function in patients with heart failure without increasing risk of adverse events. Further well-designed RCTs with long treatment durations (i.e., >1 y) and stringent heart failure inclusion criteria are necessary to confirm these findings and reduce potential biases. This trial was registered at PROSPERO as CRD42024590476.
“Not stated” does not mean nobody paid — the database does not always record it.
A meta-analysis of cohort studies linked higher intake of long-chain omega-3s to a lower risk of stroke, although the association differed between groups.
Aim of the study: We performed a meta-analysis to clarify the relationship between long chain n-3 polyunsaturated fatty acid (PUFA) intake and stroke risk. Relevant studies were identified by searching online databases through May 2015.
Results: The pooled RR of overall stroke risk for long chain n-3 PUFA intake was 0.87 [95% confidence interval (CI), 0.79-0.95]. Stratification analysis showed that higher long chain n-3 PUFAs intake was associated with reduced fatal stroke risk (RR = 0.84; 95% CI, 0.73-0.97), reduced stroke risk for BMI < 24 (RR = 0.86; 95% CI, 0.75-0.98) and reduced stroke risk for females (RR = 0.81; 95% CI, 0.71-0.92), but was not associated with stroke risk for either BMI ≥ 24 or men. This meta-analysis reveals that higher long chain n-3 PUFA intake is inversely associated with risk of stroke morbidity and mortality with BMI and sex as key factors influencing this risk. Individuals should be encouraged to manage their body weight while increasing their intake of long chain n-3 PUFAs.
“Not stated” does not mean nobody paid — the database does not always record it.
A meta-analysis of clinical trials found that omega-3 lowered some heart-failure-related markers, but did not generally improve ejection fraction or clinical outcomes.
Aim of the study: Many new clinical trials about the effect of omega-3 polyunsaturated fatty acids (PUFAs) in heart failure (HF) patients have shown inconsistent results. Therefore, a meta-analysis of randomised controlled trials (RCTs) was performed to determine the benefits of omega-3 PUFAs in HF patients.
Results: A total of nine RCTs involving 800 patients were eligible for inclusion. Compared with patients taking placebo, HF patients who received omega-3 PUFAs experienced decreased brain natriuretic peptide levels and serum norepinephrine levels. Although the left ventricular ejection fraction (LVEF) and clinical outcomes (Tei index, peak oxygen consumption) did not improve, subgroup analysis showed that the LVEF increased in dilated cardiomyopathy (DCM) patients. Overall, omega-3 PUFA supplements might be beneficial in HF patients, especially in DCM patients, but further studies are needed to confirm these benefits.
“Not stated” does not mean nobody paid — the database does not always record it.
An umbrella review found that higher fish intake may be linked to a lower risk of acute coronary syndrome, but evidence on other heart and brain conditions is limited.
Aim of the study: Fish represents one of the most important dietary sources of omega-3 polyunsaturated fatty acids, which are known to be associated with various health benefits. This study aimed to systematically review existing meta-analyses of observational studies exploring the association between fish intake and various health outcomes.
Results: This study aimed to systematically review existing meta-analyses of observational studies exploring the association between fish intake and various health outcomes. A systematic search of electronic databases was conducted to retrieve a total of 63 studies. Evidence was deemed as possible for the association between higher fish intake and decreased risk of the acute coronary syndrome, liver cancer, and depression, and limited for other outcomes (including age-related macular degeneration, Alzheimer's disease, heart failure, all-cause and coronary heart disease mortality, total and ischaemic stroke) due to heterogeneity between results and potential otherwise inexplicable confounding factors. In conclusion, results from epidemiological studies support the mechanistic effects associated with omega-3 fatty acids from high fish consumption, but evidence needs to be further corroborated with more reliable results.
“Not stated” does not mean nobody paid — the database does not always record it.
Perspectives and opinion materials
The content below presents the authors’ opinions, interpretations and hypotheses. It is not treated as equal to scientific studies and systematic reviews.
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.